NHS 为晚期子宫癌患者提供 Dostarlimab (Jemperli)，通过化疗延长预期寿命。 NHS offers Dostarlimab (Jemperli) to advanced womb cancer patients, extending life expectancy with chemotherapy.

新的癌症治疗药物 Dostarlimab 以 Jemperli 品牌出售，现已在 NHS 上为患有晚期或复发性子宫癌的女性提供服务。 New cancer treatment Dostarlimab, sold under the brand name Jemperli, is now available on NHS for women with advanced or recurring womb cancer. 该免疫治疗药物经国家健康与护理卓越研究所（尼斯）批准，与化疗一起使用可延长预期寿命。 Approved by the National Institute for Health and Care Excellence (Nice), the immunotherapy drug extends life expectancy when used with chemotherapy. 每年多达 200 名患者将受益，治疗预计将为亲人提供“宝贵的额外时间”。 Up to 200 patients will benefit each year, with the treatment expected to provide "precious extra time" with loved ones.